← Back to patent-cliff list
Adiponectin analogue (Allysta Pharmaceuticals)
Tier C — Watch / tradeAdiponectin analogue (Allysta Pharmaceuticals)
Allysta Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Adiponectin receptors
Indications (approved)：Dry eye disease, Overweight, Obesity, Dry eye syndrome
Regional status
US
Phase III
2021-05-19
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Adiponectin analogue (Allysta Pharmaceuticals)?
Approved indications include: Dry eye disease, Overweight, Obesity, Dry eye syndrome.
When does the Adiponectin analogue (Allysta Pharmaceuticals) patent expire?
No public expiry year is available for Adiponectin analogue (Allysta Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Adiponectin analogue (Allysta Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21